Bisphosphonate (BP) Treatment and Renal Impairment (RI) in Women with Postmenopausal Osteoporosis (PMO) in UK

被引：0
|
作者：
Xue, Fei [1 ]
Wentworth, Charles [2 ]
Petraro, Paul [1 ]
机构：
[1] Amgen Inc, CfOR, Thousand Oaks, CA 91320 USA
[2] Analyt Consulting Solut Inc, Wakefield, RI USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2014年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
514
引用
收藏
页码：271 / 272
页数：2
相关论文
共 50 条
  • [1] Chronic Kidney Disease (CKD) Progression Associated with Bisphosphonate (BP) Treatment in Women with Postmenopausal Osteoporosis (PMO)
    Xue, Fei
    Bartley, Yessenia
    Wentworth, Chuck
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 20 - 20
  • [2] Fracture Healing Complication (FHC) in Women with Postmenopausal Osteoporosis (PMO) Exposed to Bisphosphonate (BP) versus Other or No Osteoporosis Medication (OPM)
    Xue, Fei
    Bartley, Yessenia
    Gastanaga, Victor
    Wentworth, Chuck
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 553 - 554
  • [3] Bisphosphonate (BP) Route of Administration and Selected Health Outcomes of Interest (HOIs) among Women with Postmenopausal Osteoporosis (PMO)
    Wang, Florence T.
    Xue, Fei
    Perhanidis, Jessica
    Eva Ng
    Critchlow, Cathy
    Dore, David D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 83 - 84
  • [4] Adherence to bisphosphonate (BP) therapy for postmenopausal osteoporosis (PMO) is associated with a reduced risk of nonvertebral bone fracture
    Harris, S
    Silverman, S
    Siris, E
    Abbott, T
    Barr, C
    Rosen, C
    Geffen, D
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 799 - 799
  • [5] METANALYSIS OF CALCITONIN IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS (PMO)
    CRANNEY, A
    MOHER, D
    SHEA, B
    WELLS, G
    ADACHI, R
    TUGWELL, P
    ARTHRITIS AND RHEUMATISM, 1995, 38 (09): : 1240 - 1240
  • [6] BISPHOSPHONATES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND MILD OR MODERATE RENAL IMPAIRMENT
    Neophytou, D. P.
    Zidrou, C.
    Kyriakidis, T.
    Alvanos, D.
    Kyriakidis, A.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 342 - 343
  • [7] Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
    P. D. Miller
    E. N. Schwartz
    P. Chen
    D. A. Misurski
    J. H. Krege
    Osteoporosis International, 2007, 18 : 59 - 68
  • [8] Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
    Miller, P. D.
    Schwartz, E. N.
    Chen, P.
    Misurski, D. A.
    Krege, J. H.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 (01) : 59 - 68
  • [9] Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis
    E. Cairoli
    C. Eller-Vainicher
    F. M. Ulivieri
    V. V. Zhukouskaya
    S. Palmieri
    V. Morelli
    P. Beck-Peccoz
    I. Chiodini
    Osteoporosis International, 2014, 25 : 1401 - 1410
  • [10] Economic analysis:: Ibandronate (Bonviva®) IV injection for the treatment of postmenopausal osteoporosis (PMO) in the UK
    Cowell, W.
    Koay, A.
    Hunjan, M.
    VALUE IN HEALTH, 2006, 9 (06) : A380 - A380
12345